The Senate Health, Education, Labor & Pensions Committee today held the third in a series of bipartisan hearings on how to make prescription drugs more affordable, which focused on recent recommendations from a National Academies of Sciences, Engineering and Medicine report. In a statement submitted to the committee in June, AHA urged Congress and the administration to address the rising cost of drugs, and offered specific recommendations to increase competition, innovation and transparency, promote payment for value, improve access and align incentives. In her opening remarks at today’s hearing, Committee Ranking Member Patty Murray (D-WA) criticized the administration for reducing Medicare payments for hospital outpatient drugs under the 340B drug savings program by nearly 30% effective Jan. 1. “Not only will this do absolutely nothing to combat high drug prices, it will result in less funding for safety net providers to provide critical services to low-income and vulnerable patients,” she said. Last month, AHA joined by the Association of American Medical Colleges and America’s Essential Hospitals filed a federal lawsuit to prevent the payment cut.

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by…